Persistence of immune responses induced by Ebola virus vaccines

The following two tabs change content below.
Lancet Global Health
The Lancet Global Health is The Lancet's first gold open-access title and focuses on original research, commentary, correspondence and blogs on topics including maternal and child health, infectious and noncommunicable diseases, mental health, and more. The Editor is Zoë Mullan.

The recent devastating outbreak of Ebola virus disease led to the accelerated development of multiple candidate vaccines against this virus, with at least eight entering clinical trials in 2014–16.1 Direct evidence of 100% effectiveness against disease has been demonstrated for VSV-EBOV, a vaccine based on a replicating vesicular stomatitis virus genetically modified to express Ebola virus glycoprotein.2 This vaccine has been granted Breakthrough Therapy Designation status by the US Food and Drug Administration and PRIME status by the European Medicines Agency, and its single-dose regimen and proof of effectiveness from 10 days post-immunisation make it an attractive candidate for use in a responsive campaign (whether it be through ring immunisation around identified cases or as a whole-population intervention).

Original link:

[Comment] Persistence of immune responses induced by Ebola virus vaccines